Zastaprazan Phase 1 Clinical Trial Plan Amendment Application

Onconik Therapeutics applied to the Ministry of Food and Drug Safety on August 1, 2025, for approval of a phase 1 clinical trial plan amendment to confirm drug interactions between Zastaprazan and other marketed drugs in Korea, including Clopidogrel, Aspirin, Atorvastatin, and Apixaban.

Objectives and Expected Outcomes of the Trial

This clinical trial aims to clarify Zastaprazan’s safety profile and confirm its potential for co-administration with other drugs, broadening its scope of application. Positive results are expected to increase prescriptions by doctors, enhance patient trust, and ultimately contribute to sales growth. Furthermore, demonstrating commitment to enhancing safety through continuous R&D could boost investor confidence and positively impact stock prices.

Potential Risks and Investment Considerations

Clinical trials require time and resources, and unexpected results or delays could increase the company’s financial burden. It is important to note that clinical trial results are unpredictable, and negative results could significantly impact stock prices. Investment decisions should carefully consider the uncertainty of clinical results and macroeconomic factors. Further market analysis and competitor analysis are crucial for making informed investment decisions. Continuous monitoring of Nesuparib clinical trial results is particularly important.

Action Plan for Investors

  • Be aware of short-term stock price volatility.
  • Continuously monitor clinical trial results and Nesuparib development progress.
  • Analyze competitor and market conditions.
  • Maintain a long-term investment perspective.